Camurus’ Interim Report January-March 2020
”The number of patients treated with Buvidal® increased by 90 percent in the quarter” Summary first quarter 2020 · Total revenues of SEK 49.3 million (18.5), an increase of 167% · Product sales were SEK 48.6 million (11.0), an increase of 343% · Product sales increased by 60% compared to previous quarter · The estimated number of patients in treatment with Buvidal® increased by 90% to 7,500 in EU and Australia · A market authorization application for Buvidal was submitted to the Swiss Agency for Therapeutic Products · The Australian Therapeutic Goods Administration